First-of-its-Kind EchoGo Amyloidosis Platform Discovered for Detecting Cardiac Amyloidosis

Ultromics discovered first-of-its-kind AI-enhanced platform for detecting cardiac amyloidosis.

EchoGo Amyloidosis is an innovative platform developed to leverage artificial intelligence to analyse echocardiograms and identify the presence of cardiac amyloidosis. By harnessing the power of AI, the platform offers a promising approach to expedite the detection and diagnosis of cardiac amyloidosis, potentially leading to more efficient and accurate patient care.

The novel technology specifically aims to address the critical challenge of early diagnosis in patients with amyloidosis. Often, this condition goes undetected until it has progressed significantly, leading to delays in treatment and negatively affecting patient outcomes. 

By utilising artificial intelligence to analyse echocardiograms, EchoGo Amyloidosis provides a means to identify the presence of cardiac amyloidosis at an earlier stage. This early detection capability has the potential to improve patient outcomes by enabling timely intervention and treatment, ultimately addressing the unmet need for early diagnosis in amyloidosis patients.

Cardiac amyloidosis is a complex and heterogeneous disease that can present challenges in its diagnosis. This condition arises from the accumulation of abnormal proteins in the heart tissue. Remarkably, EchoGo Amyloidosis accomplishes this detection using just a single ultrasound view of the heart, which is a commonly obtained diagnostic image. 

FDA has granted Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection.